Skip to main content
. Author manuscript; available in PMC: 2021 May 1.
Published in final edited form as: Am J Transplant. 2019 Dec 27;20(5):1431–1438. doi: 10.1111/ajt.15737

TABLE 1.

Patient characteristics

Patient Agea (y) Sex Original disease Time to re-Tx (y) ISHLT CAV scorea Immunosuppressiona DSAa Rejectiona
1 31 M Endocardial cushion defect 15 3 CsA, MMF, Prednisone Neg. ACR
2 57 M Nonischemic cardiomyopathy 15 2 CsA, Aza, Prednisone Neg. ACR
3 5 F Idiopathic cardiomyopathy 5 2 FK506, MMF, Rapamycin Neg. -
4 28 F Restrictive cardiomyopathy 6 1b CsA, Aza, Prednisone Neg. ACR

ACR, acute cellular rejection; CAV, cardiac allograft vasculopathy; CsA, cyclosporine; DSA, donor-specific antibodies; ISHLT, International Society for Heart and Lung Transplantation; MMF, mycophenolate mofetil; AZA, azathioprine.

a

At time of retransplantation.

b

Patient 4 had congestive heart failure due to recurrent restrictive cardiomyopathy.